Compounds and compositions as kinase inhibitors
AssigneeNovartis AG
InventorsMatthew T. Burger, Savithri Ramurthy, Benjamin R. Taft
Life of this patent
Estimating the term…
Abstract
The present invention provides a compound of Formula I: wherein X, Y, Z, R1 and R2 are as described herein, and salts thereof and therapeutic uses of these compounds for treatment of disorders associated with RAF kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.
Claims6
A method of treating a proliferative disorder selected from ovarian cancer, non-small cell lung cancer and cancers driven by Ras mutations, comprising administering to a subject having said proliferative disorder a therapeutically effective amount of a compound of formula (I)
- or a pharmaceutically acceptable salt thereof;
- wherein
- R1 is selected from hydrogen and methyl;
- R2 is selected from pyridinyl and phenyl;
- wherein phenyl or pyridinyl can be substituted with a group selected from trifluoromethyl, 1,1-difluoroethyl and 2-fluoropropan-2-yl;
- X and Y are independently selected from N and C—OCH2CHR3R4;
- wherein R3 is selected from hydrogen and OH;
- and R4 is phosphonooxy;
- with the proviso that if X is N, Y is C—OCH2CHR3R4 and if Y is N, X is C—OCH2CHR3R4;
- and
- Z is selected from N and CH.
A method of treating a proliferative disorder selected from ovarian cancer, non-small cell lung cancer and cancers driven by Ras mutations, comprising administering to a subject in need thereof having said proliferative disorder a therapeutically effective amount of a compound of
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.